Boehringer Ingelheim GmbH 보도자료
Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
09월 30일 09:45
Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic colla...
Boehringer Ingelheim Boosts Immune-Oncology Pipeline Through Collaboration with ViraTherapeutics
09월 29일 11:50
Boehringer Ingelheim and ViraTherapeutics today announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to inve...
New survey reveals 9 out of 10 patients with IPF were happy with how their doctor told them about their IPF diagnosis
09월 21일 13:50
A diagnosis of IPF is news that few patients want to hear from their physician, but the reality is that approximately 3 million people worldwide are living with idio...
Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union
09월 19일 10:15
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of Glyxambi® (empagliflozin/linaglipt...
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
09월 12일 13:50
Boehringer Ingelheim today announced that the European Commission (EC) and U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib...
New analysis showed dose adjustment of Giotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer
09월 08일 15:50
Results from a new post-hoc analysis of two large Phase III trials (LUX-Lung 3 and LUX-Lung 6) assessing the impact of dose adjustments for Giotrif® (afatinib*) in p...
New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF
09월 08일 11:00
Boehringer Ingelheim presented eight IPF-related abstracts at the European Respiratory Society (ERS) International Congress 2016, including new interim data from the...
Tiotropium Respimat® improved lung function in children with asthma aged 6-17 and is well-tolerated compared to placebo in children aged 1-17[1-5]
09월 07일 11:30
Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma® trial that showed adding tiotropium Respimat® to maintenance asthma therap...
New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD
09월 06일 10:15
Boehringer Ingelheim today announced the first results from the Phase III PHYSACTO® trial that shows Spiolto® (tiotropium+olodaterol) Respimat®, combined with exerci...
Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment
09월 06일 09:55
Boehringer Ingelheim today announced a new post-hoc subanalysis of the WISDOM study that suggests only 4 out of 100 people with chronic obstructive pulmonary disease...
ESC Congress 2016 Late Breaking Science Registry
08월 30일 19:15
First outcome results from the GLORIA™-AF Registry show that treatment with dabigatran etexilate was associated with low incidences of stroke, major bleeding and lif...
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice
08월 16일 13:35
Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate).[1,2] ...
The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe
07월 20일 17:35
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. It is also a great challenge for the medical personnel treating th...
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
07월 15일 10:25
Scotland--(BUSINESS WIRE)-- Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class of ...
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
07월 14일 13:40
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of B...
1 2 3 4 5 6 7 8 9 10 11 >
Boehringer Ingelheim GmbH
상장여부 : 비상장
본사 소재지 : INGELHEIM, Germany
업종: 건강-제약
기업 개요:
등록된 회사소개가 없습니다.